You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 49 No. 5, May 1992 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ORIGINAL ARTICLES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (291)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Clinical and Biologic Response to Clozapine in Patients With Schizophrenia

Crossover Comparison With Fluphenazine

David Pickar, MD; Richard R. Owen, MD; Robert E. Litman, MD; P. Eric Konicki, MD; Rolando Gutierrez, MD; Mark H. Rapaport, MD

Arch Gen Psychiatry. 1992;49(5):345-353.


Abstract



• Twenty-one patients with schizophrenia who met criteria for neuroleptic treatment resistance or intolerance participated in a crossover, placebo-controlled, double-blind comparison of long-term typical neuroleptic and clozapine treatment. Clozapine significantly reduced total as well as positive and negative symptoms in comparison with both fluphenazine and placebo. Of the 21 patients, eight (38%) showed clozapine superiority on the basis of prospective response criteria. High levels of extrapyramidal side effects during fluphenazine treatment and later onset of illness were clinical predictors of clozapine superiority. Clozapine and fluphenazine equally reduced plasma homovanillic acid levels in comparison with placebo, although fluphenazine but not clozapine increased plasma prolactin level. A striking biologic difference between clozapine and fluphenazine was clozapine's enhancement of indexes of noradrenergic activity. Superior clozapine response was predicted by low ratios of cerebrospinal fluid homovanillic acid to 5-hydroxyindoleacetic acid, consistent with the notion that balance between dopaminergic and serotoninergic systems is important for clozapine's mechanism of action.



Author Affiliations



From the Section on Clinical Studies, Experimental Therapeutics Branch, National Institute of Mental Health, Bethesda, Md.


Footnotes



Accepted for publication October 9, 1991.

Reprint requests to Section on Clinical Studies, Experimental Therapeutics Branch, National Institute of Mental Health, National Institutes of Health, Bldg 10, Room 4N214, 9000 Rockville Pike, Bethesda, MD 20892 (Dr Pickar).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Converting from brand-name to generic clozapine: A review of effectiveness and tolerability data
Bobo et al.
Am J Health Syst Pharm 2010;67:27-37.
ABSTRACT | FULL TEXT  

A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis et al.
Arch Gen Psychiatry 2003;60:553-564.
ABSTRACT | FULL TEXT  

Clozapine and Haloperidol in Moderately Refractory Schizophrenia: A 6-Month Randomized and Double-blind Comparison
Kane et al.
Arch Gen Psychiatry 2001;58:965-972.
ABSTRACT | FULL TEXT  

A Separate Disease Within the Syndrome of Schizophrenia
Kirkpatrick et al.
Arch Gen Psychiatry 2001;58:165-171.
ABSTRACT | FULL TEXT  

Psychopharmacologic Treatment Strategies for Depression, Bipolar Disorder, and Schizophrenia
Glick et al.
ANN INTERN MED 2001;134:47-60.
ABSTRACT | FULL TEXT  

Refractory schizophrenia and atypical antipsychotics
Taylor et al.
J Psychopharmacol 2000;14:409-418.
ABSTRACT  

Childhood-Onset Schizophrenia
Bhatara et al.
Arch Gen Psychiatry 1998;55:90-92.
FULL TEXT  

The Brain Metabolic Patterns of Clozapine- and Fluphenazine-Treated Patients With Schizophrenia During a Continuous Performance Task
Cohen et al.
Arch Gen Psychiatry 1997;54:481-486.
ABSTRACT  

Atypical Antipsychotics and the Pharmacology of Olanzapine
Nihart
J Am Psychiatr Nurses Assoc 1997;3:S2-S7.
ABSTRACT  

Noradrenergic mechanisms in the prefrontal cortex
Nutt et al.
J Psychopharmacol 1997;11:163-168.
ABSTRACT  

Childhood-Onset Schizophrenia: A Double-blind Clozapine-Haloperidol Comparison
Kumra et al.
Arch Gen Psychiatry 1996;53:1090-1097.
ABSTRACT  

Clozapine: Serious Adverse Side Effects, Drug Interactions, and Other Complications of Therapy
Guith
Journal of Pharmacy Practice 1996;9:118-129.
ABSTRACT  

Clozapine for Treatment of Schizophrenia-Reply
Pickar
JAMA 1996;275:187-187.
ABSTRACT  

Clozapine Treatment of Schizophrenia
Pickar and Hsiao
JAMA 1995;274:981-983.
ABSTRACT  

Clozapine Therapy and Increases in Homovanillic Acid
Risch and Lewine
Arch Gen Psychiatry 1995;52:244-244.
ABSTRACT  

Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine
Rao et al.
Arch Gen Psychiatry 1994;51:912-917.
ABSTRACT  

Clinical Response to Clozapine in Patients With Schizophrenia
Pickar et al.
Arch Gen Psychiatry 1994;51:159-160.
ABSTRACT  

No Structural Mutation in the Dopamine D2 Receptor Gene in Alcoholism or Schizophrenia: Analysis Using Denaturing Gradient Gel Electrophoresis
Gejman et al.
JAMA 1994;271:204-208.
ABSTRACT  

Putting the 'A' in atypical: does {alpha}2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics?
Nutt
J Psychopharmacol 1994;8:193-195.
 

L-dopa helps positive but not negative features of neuroleptic-insensitive chronic schizophrenia
Owens et al.
J Psychopharmacol 1994;8:204-212.
ABSTRACT  

Muscarinic Effects of Clozapine and Negative Symptoms
Keshavan
Arch Gen Psychiatry 1993;50:835-835.
ABSTRACT  

Effects of Clozapine and Fluphenazine Treatment on Responses to m-Chlorophenylpiperazine Infusions in Schizophrenia
Owen et al.
Arch Gen Psychiatry 1993;50:636-644.
ABSTRACT  

Low Cerebrospinal Fluid Homovanillic Acid-5-Hydroxyindoleacetic Acid Ratio Predicts Clozapine Efficacy: A Replication
Risch and Lewine
Arch Gen Psychiatry 1993;50:670-670.
ABSTRACT  

Neuropharmacologic Basis for Clozapine's Unique Profile
Tandon and Kane
Arch Gen Psychiatry 1993;50:158-159.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1992 American Medical Association. All Rights Reserved.